Cardiome and Mitsubishi Tanabe Pharma Europe Enter Into an AGGRASTAT and EXEMBOL Co-Promotion Agreement in the UK

Cardiome Pharma Corp. announced that the company has entered into a Co-Promotion Agreement with Mitsubishi Tanabe Pharma Europe Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation headquartered in Japan, to co-promote Cardiome's AGGRASTAT^® (tirofiban HCL) and MTPE's EXEMBOL^® (argatroban monohydrate) in the United Kingdom. Cardiome and MTPE will co-promote the two products thereby leveraging their existing sales forces and investments in this market for an initial term of 3 years. Financial details of the agreement were not disclosed.

"We are excited to add EXEMBOL to our UK product portfolio," said Juergen Polifka, General Manager of Cardiome Europe. "In addition to increased revenues stemming from Cardiome's incremental sales of EXEMBOL within the UK market, Cardiome will also benefit from MTPE's promotion, and subsequent sales of AGGRASTAT. This partnership will result in a larger combined sales effort for both products, thereby enhancing their market penetration."

"We are pleased to enter into this co-promotion agreement with Cardiome," said Noriaki Kambayashi, MTPE's Vice-President. "We believe synergies exist between the two products providing more antithrombotic options to our hospital-based customers and benefits to patients. It will also widen availability of Exembol and increase our overall sales."

AGGRASTAT^® is indicated for the prevention of early myocardial infarction in adult patients presenting with acute coronary syndromes without ST elevation (NSTE-ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes.

Patients most likely to benefit from AGGRASTAT^® treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous coronary intervention (PCI). AGGRASTAT^® is also indicated for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI.

EXEMBOL is indicated for anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy.  The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test. However, such confirmation must not delay the start of treatment.

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS^TM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT^® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. Cardiome also commercializes Esmocard^® and Esmocard Lyo^® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, on behalf of their partner AOP Orphan Pharma in select European markets.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit www.cardiome.com.

About Mitsubishi Tanabe Pharma Europe Ltd
Mitsubishi Tanabe Pharma Europe Ltd is the European Headquarters of one of Japan's largest pharmaceutical companies, Mitsubishi Tanabe Pharma Corporation. Mitsubishi Tanabe Pharma Corporation is a research-based pharmaceutical company, created through the merger of Tanabe Seiyaku Co., and Mitsubishi Pharma Corporation on 1st October 2007, based in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is committed to becoming a global research-driven pharmaceutical company, which continuously brings new medicines to market that meet global needs. As part of the company's worldwide expansion, organisations have been established in Europe (Mitsubishi Tanabe Pharma Europe Ltd), Germany (Mitsubishi Tanabe Pharma GmbH) and North America (Mitsubishi Tanabe Pharma Development America, Inc.). For more information, please visit https://www.mt-pharma-eu.com/.